Bimzelx Dosage

Recommended Evaluations and Immunization Prior to Treatment Initiation

• Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX.
• Test liver enzymes, alkaline phosphatase and bilirubin prior to initiating treatment with BIMZELX.
• Complete all age-appropriate vaccinations as recommended by current immunization guidelines.

Recommended Dosage for Plaque Psoriasis

The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Recommended Dosage for Psoriatic Arthritis

​The recommended dosage is 160 mg by subcutaneous injection every 4 weeks.

​For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing regimen for adult patients with plaque psoriasis.

​If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Recommended Dosage for Non-Radiographic Axial Spondyloarthritis

​The recommended dosage is 160 mg by subcutaneous injection every 4 weeks.

​If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Recommended Dosage for Ankylosing Spondylitis

​The recommended dosage is 160 mg by subcutaneous injection every 4 weeks.

​If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Preparation Instructions

• Before injecting, remove the carton with BIMZELX from the refrigerator and allow BIMZELX to reach room temperature (30 to 45 minutes) without removing the prefilled syringes or autoinjectors from the carton to protect from light.
• Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit. BIMZELX injection is clear to slightly opalescent, and colorless to pale brownish- yellow. Do not use if the solution contains visible particles, is discolored or cloudy.

Administration Instructions

• BIMZELX is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of BIMZELX according to the "Instructions for Use".
• If two separate 160 mg injections are used to achieve the recommended dose, administer each injection subcutaneously at different anatomic location (such as thighs, abdomen or back of upper arm). Discard the syringes or autoinjectors after use. Do not reuse.
• Do not inject BIMZELX within 2 inches (5 cm) of the navel or into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis. Administration of BIMZELX in the upper, outer arm may only be performed by a healthcare professional or caregiver. Rotate the injection site with each injection.